Esperion Therapeutics Inc (ESPR) Reaches New 1-Year High After Analyst Upgrade

Regolare Commento Stampare

While looking at the Stock's Performance, Esperion Therapeutics, Inc. now shows a Weekly Performance of -23.89%, where Monthly Performance is 13.36%, Quarterly performance is 92.6%, 6 Months performance is 110.59% and yearly performance percentage is 64.6%. The difference between the expected and actual EPS was $-0.07/share, which represents an Earnings surprise of -5.7%. Investors will be watching to see if the name can maintain momentum heading into the new year.Since the start of the calendar year, Esperion Therapeutics, Inc. The company's market cap is $14.48 Million, and the average volume is $1.04 Million. 26,206,462 shares of the company were exchanged.

Esperion Therapeutics Inc (NASDAQ:ESPR) traded at a yearly high level of $35.14 during the last trading session. Elkfork Partners LLC purchased a new position in Esperion Therapeutics during the fourth quarter worth about $169,000. Dimensional Fund Advisors LP now owns 40,220 shares of the biopharmaceutical company's stock valued at $504,000 after buying an additional 14,257 shares during the last quarter. Dimensional Fund Advisors LP increased its position in Esperion Therapeutics by 54.9% in the fourth quarter. Finally, Virginia Retirement Systems ET AL purchased a new position in Esperion Therapeutics during the third quarter worth about $242,000. The current consensus recommendation provided by covering analysts is 2.50.

Esperion Therapeutics (NASDAQ:ESPR) last announced its quarterly earnings results on Wednesday, February 22nd.

The company's stock now has 534 Million in market capitalization. The share price has moved backward from its 20 days moving average -16.97% and positively from its 50 days moving average 17.71%. During the same period in the prior year, the firm earned ($0.58) earnings per share. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C).

Average Revenue Estimate of the company for the current Fiscal Quarter is $0, according to consensus of 6 analysts. With a targeted mechanism of action, bempedoic acid, the Company's lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.